Applications

1580 – Cardiac ablation for atrial fibrillation

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status -
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

The Prostheses List Advisory Committee (PLAC) asked MSAC to undertake a review of the comparative clinical and cost-effectiveness of cardiac ablation for AF.

See more information about PLAC's consideration of cardiac ablation for atrial fibrillation.

Service or technology in this application

Cardiac ablation for atrial fibrillation.

Type: Therapeutic

Medical condition this application addresses

Atrial fibrillation (AF) may cause symptoms of palpitations, shortness of breath and fatigue, which often leads to an impaired quality of life. It is also independently associated with an increased long-term risk of stroke, heart failure and all-cause death. Treatment involves rate or rhythm control, anticoagulant therapy and treating underlying risk factors. For rhythm control, anti-arrhythmic drug (AAD) therapy has been the cornerstone of medical management, but some patients show resistance to AAD or need to discontinue treatment due to side-effects. Cardiac ablation for the treatment of AF is increasingly being performed in symptomatic patients as an alternative to medical management, when medical management has been ineffective or not tolerated.

Application documents

Final MSAC minutes – November 2018

Outcome – Final MSAC minutes – February 2019

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 
    • 22 to 23 November 2018
    • 1 February 2019